Financial Performance - Operating revenue decreased by 16.51% to CNY 51,527,471.56 compared to the same period last year[7] - Net profit attributable to shareholders was a loss of CNY 1,252,350.59, a decrease of 58.27% compared to the same period last year[7] - Net profit attributable to shareholders after deducting non-recurring gains and losses was a loss of CNY 2,599,926.64, an increase of 13.61% in loss compared to the same period last year[7] - Basic and diluted earnings per share were both CNY -0.0022, an increase in loss of 67.16% compared to the same period last year[7] - Weighted average return on net assets was -0.13%, a decrease of 0.18% compared to the same period last year[7] - Net cash flow from operating activities decreased by 251.83% compared to the same period last year, due to a reduction in sales collections[14] - The company does not anticipate significant changes in cumulative net profit for the year compared to the previous year[19] - The company has not reported any significant changes in operational performance during the reporting period[22] Assets and Shareholder Information - Total assets increased by 34.97% to CNY 1,735,178,094.85 compared to the end of the previous year[7] - Net assets attributable to shareholders increased by 89.03% to CNY 1,246,672,873.59 compared to the end of the previous year[7] - The total number of ordinary shareholders at the end of the reporting period was 42,793[10] - The largest shareholder, Beijing Jinshang Alliance Investment Management Co., Ltd., held 24.99% of the shares, amounting to 143,291,139 shares[10] Cash Flow Activities - Cash flow from operating activities showed a net outflow of CNY 101,281,477.68, a decrease of 251.83% compared to the same period last year[7] - Net cash flow from investing activities increased by 232.40% compared to the same period last year, due to the investment of 410 million yuan in Suzhou Rongtai Fengxi Company[14] - Net cash flow from financing activities increased by 465.68% compared to the same period last year, due to funds raised from a targeted issuance[14] Asset Restructuring and Regulatory Compliance - The company is currently undergoing a major asset restructuring, with the stock suspended since April 20, 2015[15] - The company received feedback from the China Securities Regulatory Commission regarding its application for asset purchase approval, requiring a written response within 30 working days[15] - The company has committed to not changing its registered location or main business for three years and to avoid transferring control to unrelated third parties[17] - The company has been in communication with public investors regarding the progress of major asset restructuring[22] - The company has responded to inquiries from the Shenzhen Stock Exchange regarding restructuring[22] Investments and Future Plans - The company is focused on the progress of its non-public stock issuance[22] - The company is constructing a new factory, with updates provided to investors[22] - There were no securities investments during the reporting period[20] - The company did not engage in derivative investments during the reporting period[21] - The company has not held equity in other listed companies during the reporting period[20] - The company has not provided any materials to investors during the communication sessions[22] Receivables and Prepayments - Accounts receivable decreased by 86.64% compared to the beginning of the year due to the maturity and settlement of certain receivables[14] - Prepayments increased by 119.39% compared to the beginning of the year, mainly due to an increase in equipment payments[14] - Financial assets available for sale increased by 293.59% compared to the beginning of the year, attributed to an investment of 410 million yuan in Suzhou Rongtai Fengxi Company[14] - Total assets increased by 34.97% compared to the beginning of the year, primarily due to funds raised from a targeted issuance[14]

Financial Performance - The company reported a revenue of ¥91,300,091.48, a decrease of 1.22% compared to the same period last year[20]. - The net profit attributable to shareholders was ¥8,413,630.26, down 7.92% year-on-year[20]. - The net profit after deducting non-recurring gains and losses was ¥6,531,781.02, reflecting a significant decline of 45.26% compared to the previous year[20]. - The net cash flow from operating activities was negative at ¥94,888,086.95, a decrease of 225.04% from the same period last year[20]. - Operating costs increased by 20.14% to ¥43,738,662.93, impacting overall profitability[29]. - The gross profit margin for the pharmaceutical manufacturing segment was 52.09%, down 8.52% from the previous year[32]. - The product "Zhuanggu Shenjing" saw a revenue increase of 7.22% to ¥10,626,016.21, while its cost rose by 23.32%[32]. - The company reported a net loss of CNY 805,339,969.67, slightly improved from a loss of CNY 813,753,599.93 in the previous period[108]. - The total profit for the first half of 2015 was CNY 7,891,494.00, a decrease of 8.01% compared to CNY 8,576,423.18 in the previous year[115]. Assets and Liabilities - Total assets increased by 36.22% to ¥1,751,236,561.12 compared to the end of the previous year[20]. - The net assets attributable to shareholders rose by 89.22% to ¥1,247,925,224.18 compared to the end of the previous year[20]. - Total liabilities decreased to CNY 503,311,336.94 from CNY 626,089,214.99, a reduction of about 19.6%[108]. - The company's equity attributable to shareholders rose to CNY 1,247,925,224.18 from CNY 659,496,066.49, reflecting an increase of approximately 89.4%[108]. - The total liabilities decreased to 1,371.00 million yuan from 1,371.00 million yuan in the previous period, indicating stable financial health[129]. Cash Flow - The net cash flow from financing activities was ¥508,871,264.83, a remarkable increase of 52,187.75% attributed to funds raised from a targeted issuance[29]. - The cash inflow from sales of goods and services was ¥90,504,259.04, a slight increase from ¥89,429,842.89, indicating stable revenue generation[125]. - The company reported a total cash outflow from operating activities of ¥201,049,781.12, compared to ¥127,142,889.26 in the previous period, highlighting increased operational costs[122]. - The total cash and cash equivalents at the end of the period amounted to ¥64,014,073.85, up from ¥11,954,026.91, indicating improved liquidity[123]. Shareholder Information - The company reported a total of 573,488,849 shares outstanding after a non-public offering of 124,472,573 new shares, increasing the total share capital from 449,016,276 shares[84]. - The earnings per share (EPS) decreased from 0.0187 to 0.0147 after the share issuance, indicating a dilution effect on existing shareholders[85]. - The net asset value per share dropped from 2.78 to 2.18 following the issuance of new shares, reflecting a decrease in the company's per-share equity value[85]. - The number of ordinary shareholders at the end of the reporting period was 41,116, indicating a stable shareholder base[90]. - Beijing Jinshang Alliance holds 24.99% of the shares, while Jinshang Alliance Holdings holds 7.36%, maintaining their positions as major shareholders[90]. Corporate Governance and Compliance - The company has not faced any penalties or rectification issues during the reporting period, indicating compliance with regulatory requirements[78]. - The company has committed to not changing its registered location or main business for three years, ensuring stability in its operations[75]. - The company has undertaken measures to minimize and regulate related party transactions, committing to fair pricing and compliance with legal procedures[76]. - The company has not conducted an audit of its semi-annual financial report, which may affect the reliability of the financial data presented[77]. Future Plans and Strategies - The company plans to enhance its technical transformation and actively prepare for GMP certification[28]. - The company adjusted its sales policies and increased market development efforts in response to changing sales environments[28]. - The company has plans for market expansion and new product development, although specific figures were not disclosed in the report[132]. - The company is focusing on research and development of new technologies to enhance its competitive edge in the pharmaceutical industry[132]. Government Grants and Subsidies - The company received government subsidies amounting to ¥300,000.00 during the reporting period[25]. - Government grants related to income are recognized as deferred income when used to compensate for future expenses or losses, and directly recognized in the current period for already incurred expenses[28]. Accounting Policies - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements accurately reflect its financial position and operating results[146]. - The company includes all subsidiaries in its consolidated financial statements, treating the entire corporate group as a single accounting entity[152]. - The company measures the fair value of assets and liabilities acquired in business combinations under non-common control, recognizing any excess as goodwill[149][154].

通化金马药业集团股份有限公司 2015 年第一季度报告正文 证券代码：000766 证券简称：通化金马 公告编号：2015-20 通化金马药业集团股份有限公司 2015 年第一季度报告正文 1 通化金马药业集团股份有限公司 2015 年第一季度报告正文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业收入（元） | 43,456,535.11 | 46,386,738.11 | -6.32% | | 归属于上市公司股东的净利润（元） | 17,893,078.84 | 19,904,686.32 | -10.11% | | 归属于上市公司股东的扣除非经常性损 益的净利润（元） | 17,293,283.44 | 19,918,028.88 | -13.18% | | 经营活动产生的现金流量净额（元） | -21,904,420.00 | 50,131,950.01 ...

Financial Performance - The company reported a total revenue of RMB 1.2 billion for the year 2014, representing a year-on-year increase of 15%[20] - The net profit attributable to shareholders was RMB 200 million, which is a 10% increase compared to the previous year[20] - The company achieved operating revenue of ¥208,414,737.57, an increase of 41.03% compared to the previous year[28] - Net profit attributable to shareholders was ¥5,165,646.75, reflecting a growth of 26.23% year-over-year[28] - The net profit after deducting non-recurring gains and losses surged by 447.74% to ¥12,567,301.50[28] - The company reported a significant decrease in net cash flow from operating activities, down 66.67% to ¥34,317,920.13[28] - The company reported a net profit of 20.92 million RMB from its investment in Changchun Rural Commercial Bank, holding 12 million shares, which is 10% of the total equity[58] - The company’s financial condition is reported to be stable, with a focus on investing in the health industry to build a health industry platform[114] - The company reported a net loss of CNY 813,753,599.93, slightly improved from a loss of CNY 818,919,246.68 in the previous year[171] - The company’s total comprehensive income for the period was a loss of 8,615 million yuan, compared to a gain of 4,092 million yuan in the previous period, indicating a significant downturn[196] Investment and Development - The company plans to invest RMB 50 million in research and development for new products in the upcoming year[20] - The company is focusing on the development of innovative drug delivery systems, with a projected launch in Q3 2015[20] - The company has completed the acquisition of a local pharmaceutical firm, enhancing its product portfolio[20] - The company holds 109 drug registration certificates, including 12 exclusive varieties, and has applied for 8 patents, of which 5 have been granted[46] - The company aims to achieve a balance between long-term and short-term goals, focusing on financial targets, key product objectives, and team development[61] - The company has committed to injecting at least CNY 500 million into the company or other quality assets within 18 months, primarily for GMP certification, industry mergers, new product development, and marketing channel construction[100] Market and Customer Growth - User data indicates a growth in customer base by 20%, reaching a total of 1 million active users[20] - The company is exploring market expansion opportunities in Southeast Asia, aiming for a 5% market share by 2016[20] - The company has outlined a future outlook with a revenue growth target of 12% for 2015[20] Risks and Challenges - The company has identified potential risks related to regulatory changes and market competition, advising investors to remain cautious[11] - The company faces risks from drug price reductions and uncertainties in product bidding processes, which may impact growth and profit margins[62] Governance and Compliance - The company maintains a strong governance structure, ensuring compliance with relevant laws and regulations to protect the rights of all shareholders and creditors[73] - The company has revised its profit distribution policy to ensure compliance and transparency, protecting the rights of minority shareholders[68] - The company has established a strict insider information management system, with no incidents of information leakage reported during the reporting period[135] - The company has a structured remuneration decision-making process based on its salary management system and performance evaluations[125] Shareholder Information - The company will not distribute cash dividends or issue bonus shares for the year 2014[5] - The company has not distributed any cash dividends in the past three years, with a total cash dividend amount of 0.00 yuan for 2014, 2013, and 2012[71] - The company's net profit for 2014 was entirely used to offset previous years' losses, resulting in no cash profit distribution or capital reserve transfer plan[72] - The cash dividend policy is compliant with the company's articles of association and shareholder resolutions, ensuring that minority shareholders' rights are adequately protected[71] Employee and Management Structure - The company has a total of 872 employees, with 755 in the parent company and 117 in subsidiaries[130] - Employee composition includes 434 production staff, 159 sales personnel, 73 technical staff, 30 finance staff, and 176 administrative staff[130] - The management team includes experienced professionals, with the general manager having a tenure since June 24, 2014, and other executives also being reappointed on the same date[127] Financial Position and Assets - Total assets grew by 16.13% to ¥1,285,585,281.48 at year-end[28] - The company's total assets at the end of the reporting period were 16,270 million yuan, a decrease from 53,599 million yuan in the previous period, indicating a decline of approximately 69.7%[194] - The company’s total liabilities at the end of the reporting period were 5,281 million yuan, which is a decrease from 8,108 million yuan in the previous period, indicating a reduction of approximately 34.8%[194] Cash Flow and Financing Activities - Total cash inflow from financing activities increased by 120.31% year-on-year, attributed to new bank loans[39] - Cash outflow from financing activities surged by 5,626.56% compared to the previous year, due to repayment of bank loans[39] - The net increase in cash and cash equivalents rose by 377.74% year-on-year, driven by increased sales receipts and new bank loans[39] - The total cash and cash equivalents at the end of the period reached 53,412,273.20 CNY, up from 14,873,188.45 CNY, representing a growth of 258.5%[187]

Financial Performance - Operating revenue for the current period reached CNY 61,719,390.17, a 61.69% increase year-on-year[7] - Net profit attributable to shareholders was CNY -3,001,355.68, reflecting a significant decline of 887.51% compared to the same period last year[7] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY -3,009,490.74, a decrease of 797.23% year-on-year[7] - The weighted average return on net assets was -0.45%, down from 0.93% in the previous year[7] - The basic earnings per share for the current period was CNY -0.0067, a decrease of 857.14% compared to the same period last year[7] - Net profit rose by 33.87% to CNY 6.14 million, attributed to higher operating revenue and investment income[14] - There are no significant changes expected in the cumulative net profit for the year compared to the previous year, indicating stability in financial performance[22] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was CNY 66,707,427.11, an increase of 35.16%[7] - Cash flow from operating activities improved by 35.16% to CNY 66.71 million, due to increased sales collections and repayments from counterparties[16] - The company’s cash and cash equivalents increased by 147.83% to CNY 46.48 million, primarily due to higher sales collections[14] - Accounts receivable decreased by 48.30% to CNY 46.27 million, following a debt settlement with a related party[14] - Prepayments rose by 206.70% to CNY 145.38 million, reflecting advance payments for equipment procurement[14] - Total assets increased by 13.15% to CNY 1,252,571,291.81 compared to the end of the previous year[7] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 42,295[10] - The top shareholder, Beijing Evergreen Ivy Investment Management Co., Ltd., held 17.82% of the shares, totaling 80,000,000 shares[10] Expenses and Financial Management - Financial expenses surged by 239.35% to CNY 4.97 million, resulting from increased bank loans and interest expenses from borrowing from major shareholders[14] - Sales expenses increased by 43.43% to CNY 62.10 million, due to higher costs for market promotion and sales expansion[14] Investments and Projects - The company’s construction in progress increased by 44.58% to CNY 193.20 million, attributed to the construction of a new plant[14] - The company is in the process of a non-public stock issuance, which was accepted by the China Securities Regulatory Commission on August 8, 2014[17] - The company has not engaged in any securities or derivative investments during the reporting period, maintaining a conservative investment strategy[23] Corporate Governance - The company has committed to avoiding competition with its subsidiaries and will not engage in any competing business after the completion of the equity change[20] - The company has issued a commitment to reduce and regulate related party transactions, aiming to minimize such transactions and ensure fair pricing[20] Communication and Transparency - The company has been actively communicating with public investors regarding the progress of its new factory construction and non-public stock issuance[24]

Financial Performance - The company achieved operating revenue of CNY 92,427,565.79, an increase of 41.55% compared to the same period last year[19]. - Net profit attributable to shareholders reached CNY 9,137,559.30, reflecting an 86.83% increase year-on-year[19]. - The net profit after deducting non-recurring gains and losses was CNY 11,931,445.63, a significant increase of 369.91% compared to the previous year[19]. - Basic earnings per share rose to CNY 0.0204, up 87.16% from the previous year[19]. - The total profit for the current period is CNY 8,576,423.18, compared to CNY 3,719,946.73 in the previous period, showing an increase of 130.5%[107]. - The total comprehensive income for the current period is CNY 9,137,559.30, compared to CNY 3,913,071.11 in the previous period, indicating an increase of 133.0%[107]. - The company reported a net profit of ¥9,137,559, contributing positively to the equity attributable to shareholders[119]. Cash Flow - The net cash flow from operating activities was CNY 75,883,764.67, a remarkable increase of 4,637.77% year-on-year[19]. - The cash flow from operating activities for the current period is CNY 75,883,764.67, a significant increase from CNY 1,601,677.78 in the previous period[113]. - The net cash flow from operating activities was ¥79,566,663.45, a significant improvement compared to a negative cash flow of ¥403,112.60 in the previous period, indicating a positive operational performance[117]. - Total cash inflow from operating activities reached ¥186,257,272.20, up from ¥84,044,139.61, reflecting a year-over-year increase of approximately 121%[117]. - The ending balance of cash and cash equivalents was ¥9,894,023.81, a decrease from ¥20,691,063.97 in the previous period, reflecting a decline of approximately 52%[118]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,156,680,176.10, an increase of 4.49% from the end of the previous year[19]. - Total liabilities were reported at ¥415,348,777.15, an increase from ¥363,896,633.62, representing a rise of 14.1%[104]. - Current assets totaled ¥510,747,532.34, an increase of 9.2% from ¥467,380,552.65 at the beginning of the period[103]. - Non-current assets increased to ¥649,472,244.73, up from ¥612,252,316.69, reflecting a growth of 6.1%[104]. - The total owner's equity at the end of the current period is 724,878,600 yuan, showing a change from the previous period's 720,524,000 yuan[128]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 44,040[84]. - The total number of shares before the change was 449,016,276, with no changes in the number of shares during the reporting period[83]. - The largest shareholder, Changchun Yungxin Investment Co., Ltd., transferred 80,000,000 shares to Beijing Ivy League Investment Management Co., Ltd., representing 17.82% of the total share capital[132]. - Changchun Yungxin Investment Co., Ltd. retains 21,436,034 shares, accounting for 4.77% of the total share capital, making it the second-largest shareholder[132]. Operational Strategy - The company plans to enhance internal management and control costs while expanding external market development[27]. - The company plans to continue expanding its market presence and investing in new product development to drive future growth[106]. - The company has committed to injecting at least 500 million RMB into the business for GMP certification, industry mergers and acquisitions, new product development, and marketing channel construction within 18 months of completing the equity transfer registration procedures[74]. Governance and Compliance - The company has maintained a compliant governance structure in accordance with relevant laws and regulations[52]. - The company has not experienced any major litigation or arbitration matters during the reporting period[53]. - The company has not engaged in any significant related party transactions during the reporting period[60]. - The company will ensure compliance with relevant regulations and company management systems while exercising shareholder rights[75]. Financial Reporting - The company prepares financial statements based on the going concern principle and adheres to the accounting standards issued by the Ministry of Finance[133]. - The financial statements reflect the company's financial position, operating results, changes in shareholders' equity, and cash flows accurately and completely[134]. - The company’s financial report for the half-year was not audited[97]. - The company has not audited its semi-annual financial report[76]. Investment and Assets Management - The company has not made any asset acquisitions or sales during the reporting period[56][57]. - The company has not reported any new product launches or technological advancements in the current period[126]. - The company recognizes impairment losses for financial assets if there is objective evidence of impairment, with specific criteria for available-for-sale financial assets and held-to-maturity investments[155].

Financial Performance - The company's operating revenue for 2013 was CNY 147,781,836.93, representing a 15.77% increase compared to CNY 127,647,611.13 in 2012[21]. - The net profit attributable to shareholders for 2013 was CNY 4,092,133.24, a 6.11% increase from CNY 3,856,634.96 in 2012[21]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 57.26% to CNY 2,294,378.70 from CNY 5,368,189.38 in 2012[21]. - The net cash flow from operating activities significantly improved to CNY 102,962,801.99, a 1,685.45% increase from a negative CNY 6,494,214.11 in 2012[21]. - Total assets at the end of 2013 reached CNY 1,106,992,392.01, marking a 23.7% increase from CNY 894,890,628.51 at the end of 2012[21]. - The net assets attributable to shareholders decreased slightly by 0.73% to CNY 615,080,936.63 from CNY 619,604,800.37 in 2012[21]. - The basic earnings per share remained stable at CNY 0.01, unchanged from 2012[21]. - The diluted earnings per share also remained at CNY 0.01, consistent with the previous year[21]. - The weighted average return on net assets increased to 0.69% from 0.63% in 2012[21]. Revenue and Expenses - Total revenue for the period was ¥147,781,836.93, reflecting a 15.77% growth year-over-year[32]. - The total cost of sales increased by 23.58% to ¥173,170,718.85, indicating rising operational expenses[33]. - Research and development expenses amounted to ¥6,422,053.47, which is 4.35% of total revenue[40]. - Sales expenses rose by 42.97% to ¥48,437,795.24, driven by increased market promotion efforts[39]. Cash Flow and Investments - Operating cash inflow increased by 75.06% to ¥299,337,250.33, while operating cash outflow rose by 10.64%[42]. - Investment cash inflow increased year-on-year mainly due to dividends received from Changchun Rural Commercial Bank and cash from the sale of remaining equity in Shuanglong Chemical[43]. - Investment cash outflow increased year-on-year due to equipment and construction costs for new facilities and an investment of 67.65 million yuan in Changchun Rural Commercial Bank[43]. - Financing cash inflow increased year-on-year due to a 30 million yuan short-term loan from the bank, a 60 million yuan loan from major shareholder Beijing Changqing Teng Lianchuang Investment Management Co., Ltd., and 14.4 million yuan in government subsidies for new project construction[43]. Market and Product Performance - Revenue from the pharmaceutical industry reached 147.65 million yuan, with a year-on-year increase of 15.97% and a gross margin of 51.53%[44]. - The company reported a significant increase in revenue for the product "Xiao Ai Ping Pian" by 107.83% year-on-year, with a gross margin of 69.26%[44]. Shareholder and Governance Matters - The company plans not to distribute cash dividends or issue bonus shares for the year[5]. - The company has not distributed any cash dividends in the past three years, with all profits used to offset previous losses[86]. - In 2013, the total cash dividend amount was 0.00, representing 0% of the net profit attributable to shareholders[87]. - The company has established a governance structure to protect the rights of all shareholders and creditors[88]. - The company has revised its profit distribution policy to ensure compliance and transparency, providing opportunities for minority shareholders to express their opinions[85]. Risks and Future Strategies - The company faces risks from fluctuating raw material costs and potential impacts from ongoing healthcare reforms, which may pressure profit margins[79]. - The company aims to enhance its market development and strengthen core products to achieve sustainable and rapid growth in the pharmaceutical industry[79]. - The company’s future development strategy includes a focus on innovation and expanding its product offerings in response to market competition[79]. Internal Control and Compliance - The company has established a comprehensive internal control system, which effectively executed and improved operational management and risk prevention capabilities[184]. - The audit report issued by Zhongzhun Accounting Firm confirmed that the company maintained effective internal control over financial reporting in all material respects as of December 31, 2013[188]. - The company has not experienced any significant accounting errors or omissions during the reporting period, ensuring the accuracy of financial disclosures[189]. Employee and Management Structure - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 8,095,000 CNY, with an additional 1,200,000 CNY from shareholder units, totaling 9,295,000 CNY[153]. - The company employed a total of 899 staff members, with 440 in production, 164 in sales, 73 in technology, 30 in finance, and 192 in administration[157]. - The management team saw changes with the appointment of Wang Fuli as General Manager on May 21, 2013, following the departure of Wu Chengyu[155]. Shareholder Transactions - A total of 8,000,000 shares were transferred from Tonghua City Yongxin Investment Co., Ltd. to Beijing Changqing Teng Investment Management Co., Ltd. after approval from the State-owned Assets Supervision and Administration Commission[131]. - The company has initiated a non-public stock issuance, which has been approved by the board of directors, supervisory board, and shareholders' meeting, with materials being prepared for submission to the China Securities Regulatory Commission[129].